Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 47 for “"BRAF mutations"”.
-
Genetics of cutaneous malignant melanoma
… analysis of these families shows germline mutations of CDKN2A in 20-30% of patients. This thesis has investigated 48 Scottish families with cutaneous malignant melanoma and also 28 patients with sporadic melanoma for mutations in the CDKN2A, MCIR and BRAF genes using molecular genetic …
-
INTRINSIC AND SYSTEMIC REGULATION OF BRAF: UNCOVERING NEW REGULATION WITH NOVEL MUTATIONS AND MOUSE MODEL, ULTIMATELY ESTABLISHING NOVEL TARGETING SMALL MOLECULES
… protein kinases, including three isoforms, CRAF, BRAF, and ARAF, which functions as a core component of RTK-RAS-RAF-MEK-ERK signaling and plays a central role in cell biology. RAF is a dominant target of oncogenic mutations. Although targeting RAF with kinase inhibitors has achieved promising …
-
New therapeutic concepts for BRAF-driven colorectal cancer
The kinase-activating BRAFV600E mutation occurs in about 10 % of colorectal cancer (CRC) patients and confers a poor prognosis. In order to evaluate novel treatment approaches such as the combination of immunotherapy with kinase inhibition, syngeneic preclinical models are urgently needed, but …
-
Μελέτη της έκφρασης των γονιδίων EGFR, RAS που εμπλέκονται στο μονοπάτι μεταγωγής σήματος του υποδοχέα του επιδερμικού αυξητικού παράγοντα σε συμπαγείς όγκους
… study we investigated the presence of KRAS / BRAF mutations and their correlation with the clinical-histopathological parameters in 322 patients with colon cancer. In addition, we collected fresh paired tumor and normal tissue from 50 patients and investigated the expression level of KRAS and …
-
Potential Targeted Therapeutic Strategies for Overcoming Resistance in BRAF Wild Type Melanoma
… 50% of all melanoma patients possess activating BRAF mutations ignited a significant paradigm shift in the way the melanoma field approached research and how patients were treated [1]. The era of targeted therapy had begun and with it came successful targeted BRAF inhibitor therapy regimens, …
-
Identification of therapeutic targets in canine bladder cancer: a translational model for MAPK pathway-targeted and immune-based therapies
Activating mutations in the proto-oncogene BRAF are drivers of oncogenesis in several human cancers, including melanoma, thyroid and colorectal carcinomas, and hairy-cell leukemia. Small molecule inhibitors targeting oncogenic BRAF demonstrate initial efficacy in approximately 50% of BRAF mutant …
-
Protein kinase C δ is a potential therapeutic target in malignant melanoma with NRAS mutation or B-RAF inhibitor-resistance
… the impressively high rates of response to BRAF inhibitors in patients with melanomas harboring BRAF mutations, most of these patients eventually relapse after developing resistance to the drug, due in part to secondary mutations in NRAS. Although NRAS mutation is the second most common …
-
Expression of BRAF V600E mutation in osteoclasts: a murine model of bone erosion in histiocytosis-like disease
BRAF is a serine/threonine protein kinase which regulates proliferation, differentiation, and apoptosis of cells as a downstream effector in the RAS-RAF-MEK-ERK/MAPK signaling pathway. Activating mutations in the BRAF gene can induce excessive cell growth and survival and are found in a wide range …
-
Morphologische Charakterisierung der BRAF mutierten Melanome mittels Immunhistochemie, Dermatoskopie und konfokaler Laserscanmikroskopie
… can be distinguished based on the presence of BRAF mutations. Estimated 40-60% of melanomas harbour a BRAF mutation, most of them V600E. Current guidelines recommend testing every advanced melanoma for BRAF mutation, since BRAF inhibitors are available for both adjuvant and therapeutic setting. …
-
Συσχέτιση των πολυμορφισμών του γονιδίου της θυμιδιλικής συνθάσης και των μεταλλάξεων των γονιδίων KRAS και BRAF, με τα κλινικά χαρακτηριστικά ασθενών με ορθοκολικό καρκίνο που λαβαίνουν χημειοθεραπεία με φλουοροπυριμιδίνες
… thymidylate synthase (TYMS) gene and the KRAS/BRAF mutations have been investigated for their prognostic value in colorectal cancer (CRC) in order to identify patients who will benefit from the administered chemotherapy and to tailor treatment decisions. This study investigated the potential …
-
Ανίχνευση του μεταλλαγμένου γονιδίου KRAS σε κυκλοφορούν ελεύθερο DNA πλάσματος και του μεταγράφου του σε αιμοπετάλια ασθενών με καρκίνο του παχέος εντέρου και μελέτη της κλινικής τους χρησιμότητας στην παρακολούθηση της νόσου
… NGS technique aiming at the identification of mutations in 23 genes. At the same time NGS was also applied in circulating tumor DNA isolated from patient’s plasma aiming at identification of possible mutations in a broad gene panel and furthermore investigation of KRAS mutations using digital …
-
Μοριακή και ανοστοϊστοχημική διερεύνηση της μικροδορυφορικής αστάθειας (MSI) σε καρκινώματα παχέος εντέρου
… sequencing were applied to identify KRAS, BRAF, NRAS mutations and Microsatellite instability (MSI) status. Immunohistochemistry was used to characterize the associated Mismatch Repair Protein loss. Statistical calculations were performed using the statistical package SPSS v21.0. Results: …
-
BRAF V600E mutacijos ir citomorfologinių požymių reikšmė papilinio skydliaukės vėžio diagnostikos optimizavimui /
… disease course. The first works on the impact of BRAF mutations in oncological diseases were performed in studies of skin, colon and lung tumors. The link between BRAF mutations and PTC was confirmed in publications in 2003. A high V400E mutation specificity for PTC was noticed at that time. …
-
The significance of the BRAF V600E mutation and the cytomorphological features for the optimization of papillary thyroid cancer diagnostics /
… disease course. The first works on the impact of BRAF mutations in oncological diseases were performed in studies of skin, colon and lung tumors. The link between BRAF mutations and PTC was confirmed in publications in 2003. A high V400E mutation specificity for PTC was noticed at that time. …
-
Μεταλλαγές και έκφραση των ογκογονιδίων RAS και BRAF στον καρκίνο της ουροδόχου κύστης
… society. We determined RAS codon 12 and 13 point mutations and evaluated mRNA expression levels in transitional cell carcinoma cases. Mutational activation of the MAP kinase pathway is frequently found in many types of cancer. Recently, activating mutations in the BRAF gene, an important activator …
-
Targeted Oncogene Mutation Detection in Non-Small Cell Lung Cancer by Multiplexed Array Mass Spectrometry Genotyping: Results of a Clinical Validation Study
… discovery of cancer driver genes and somatic mutations in lung cancer patient sub-groups has seen the emergence of genetic abnormalities being used in the treatment of lung cancer as predictive bio-markers and molecular targets for targeted cancer therapy especially in Non-small Cell Lung …
-
Μεταλλάξεις και πολυμορφισμοί στα εξόνια 1 και 2 του γονιδίου HRAS και στο εξόνιο 15 του γονιδίου BRAF σε πάσχοντες από ακανθοκυτταρικό καρκίνωμα της στοματικής κοιλότητας στον ελληνικό πληθυσμό
… detected absence of hotspot PIK3CA gene mutations in the Greek population, we hypothesized that the HRAS might be activated as upstream effector of the pathway. Furthermore, the status of the BRAF mutations in OSCC has never been assessed before in the Greek population. Eighty six primary …
-
Proteomic and molecular analysis in colorectal cancer: validation of the biomarkers desmin, SET and CK8.
… 73 and 431 residues and 50% of CRC patients have mutations in the EGFR/Ras/Raf/MEK/ERK signalling pathway (KRAS or BRAF mutations) resulting in constitutive ERK activation. Inhibition of EGFR activation in Caco2 cells showed a significant decrease (P<0.0001) in PS73 and PS431 levels by 59% and 65% …
-
Ανίχνευση προγνωστικών και προβλεπτικών δεικτών σε ασθενείς με χειρουργημένο ορθοκολικό καρκίνο που λαμβάνουν συμπληρωματική χημειοθεραπεία με συνδυασμό φλουροπυριμιδινών και Oxaliplatin
… expression profile in proportion with KRAS and BRAF mutational status and likewise with Microsatellite Instability (MSI). Also, to study the expression of genes associated either with the increase of metastatic potential such as NEDD9, PKM2, cMYC or with resistance to LOHP and 5FU such as ERCC1 …
-
Mismatch Repair Deficient Tumors Lacking Known Sporadic Causes: Are They All Due to Lynch Syndrome?
… absence of MLH1 promoter hypermethylation and BRAF mutations are suggestive of Lynch syndrome (LS). Positive germline genetic test results confirm LS. It is unclear if individuals with MMRD tumors but no identified germline mutation or sporadic cause (MMRD+/germline-) have LS. HYPOTHESIS: Since …
Page 1 of 3